Explore evidence

6.45 aORPrevious virologic nonsuppression was associated with an adjusted odds ratio of 6.45 (95% CI: 5.81–7.16) for subsequent virologic nonsuppression among people with HIV on tenofovir, lamivudine, and dolutegravir (TLD).

NigeriaVIH/sidapublished 2024AIDS (London, England)PubMeddocument of 8 observations

8 %8% of patients had documentation of a 12-month viral load measurement.

NigeriaVIH/sidapublished 2019PloS onePubMeddocument of 7 observations

0.3 odds_ratioEducation was negatively associated with fertility desire among HIV-positive women (OR = 0.30, 95% CI: 0.12–0.74).

NigeriaVIH/sidaobserved 2015published 2021African journal of AIDS research : AJARPubMeddocument of 5 observations

4 %Of the 8,329 eligible women in the 2018 Nigerian National Nutrition and Health Survey, 180 (4.0%) missed HIV testing after participating in pre-test counselling.

NigeriaVIH/sidaobserved 2018published 2022African journal of reproductive healthPubMeddocument of 5 observations

1,800,000 personsIn 2018, an estimated 1.8 million persons living in Nigeria had HIV infection, representing 1.3% of the total population.

NigeriaVIH/sidaobserved 2018published 2021MMWR. Morbidity and mortality weekly reportPubMeddocument of 6 observations

44.2 %Among 240 booked pregnant women in Oyo state, 44.2% of HIV-negative respondents reported being abused in the index pregnancy.

NigeriaVIH/sidaobserved 2019published 2023Journal of the International Association of Providers of AIDS CarePubMeddocument of 6 observations

10,015 participantsA total of 10015 participants representing 14.4% of ART clients in 50 hospitals opted for the community pharmacy ART refill model.

NigeriaVIH/sidaobserved October 2016 to February 2018published 2021Research in social & administrative pharmacy : RSAPPubMeddocument of 6 observations

2,500 NGNThe median maximum amount people living with HIV (PLHIV) on antiretroviral therapy (ART) were willing to pay for viral load testing services was NGN2,500 (USD $6.94), with an interquartile range of NGN1,000–NGN5,000.

NigeriaVIH/sidaobserved July and August 2019published 2023PloS onePubMeddocument of 9 observations

99.12 %Viral suppression was 99.12%.

NigeriaVIH/sidaobserved October 2016 to February 2018published 2021Research in social & administrative pharmacy : RSAPPubMeddocument of 6 observations

21 casesTwenty-one (95.5%) high risk infants had their first PCR screening between 3 and 14 months.

NigeriaVIH/sidapublished 2025West African journal of medicinePubMeddocument of 8 observations

24.3 %Rifampicin resistance was observed in 9 out of 37 (24.3%) HIV-positive tuberculosis patients in the North Central zone of Nigeria.

Nigeriatuberculose · VIH/sidapublished 2019Journal of epidemiology and global healthPubMeddocument of 7 observations

The control group had no appreciable reduction in the proportion of respondents with low dietary diversity three months after the intervention.

NigeriaVIH/sidaobserved three months after the interventionpublished 2023African health sciencesPubMeddocument of 3 observations

9.1 %HIV sero-positive patients had higher odds of mixed intestinal parasites than HIV sero-negative patients (9.1% versus 3.9%).

Nigeriaintestinal parasites · VIH/sidapublished 2011Acta tropicaeurope_pmcdocument of 5 observations

4 %4% of the participants disclosed their HIV status to their boy/girlfriends.

NigeriaVIH/sidapublished 2022AIDS carePubMeddocument of 12 observations

48.9 %Among patients with ≥2 viral load measurements on tenofovir, lamivudine, and dolutegravir (TLD), viral resuppression to ≤50 copies/ml at follow-up occurred in 48.9% of those with initial virologic nonsuppression (≥1000 copies/ml).

NigeriaVIH/sidapublished 2024AIDS (London, England)PubMeddocument of 8 observations

29.2 %Sleeping disorders were reported by 29.2% of women living with HIV.

NigeriaVIH/sidapublished 2025West African journal of medicinePubMeddocument of 10 observations

36.1 %Among 5928 persons living with HIV who initiated antiretroviral therapy with at least 6-month follow-up and one CD4 measurement, 2140 (36.1%) received tenofovir-containing regimens.

NigeriaVIH/sidapublished 2020AIDS research and therapyPubMeddocument of 12 observations

26.5 %Depression was reported by 26.5% of women living with HIV.

NigeriaVIH/sidapublished 2025West African journal of medicinePubMeddocument of 10 observations

3.18 AORPeople living with HIV had adjusted odds ratio (AOR) of 3.18 for cutting meal sizes as a food security measure, with 95% confidence interval 2.60–3.88.

NigeriaVIH/sidapublished 2022AIDS and behaviorPubMeddocument of 4 observations

3.5 %The prevalence of prolonged QTc interval was 3.5% in HIV-positive children.

NigeriaVIH/sidapublished 2020The Nigerian postgraduate medical journalPubMeddocument of 9 observations

2,000,000 individualsNigeria has approximately 2 million individuals currently infected with HIV.

NigeriaVIH/sidapublished 2025PloS onePubMed

17.6 %The majority of drug-resistant mutations observed conferred resistance to NNRTIs (17.6%).

NigeriaVIH/sidaobserved 2018published 2023AIDS (London, England)PubMeddocument of 3 observations

51.1 %23 respondents (51.1%) could use up to 80% and above of the test strips given within the period.

NigeriaVIH/sidaobserved 2019published 2024BMC primary carePubMeddocument of 8 observations

14 %Among adolescents and youths living with HIV in Nigeria, facility characteristics explained 14% to 22.22% of the observed variance in retention in care across age groups.

NigeriaVIH/sidapublished 2020BMJ global healthPubMeddocument of 7 observations

74 %74% of female artisans in Ibadan, Nigeria had ever screened for HIV.

NigeriaVIH/sidapublished 2025Women's health (London, England)PubMeddocument of 7 observations